key: cord-0078827-hrx0l65r
authors: Winthrop, Kevin L.; Skolnick, Alan W.; Rafiq, Adnan M.; Beegle, Scott H.; Suszanski, Julian; Koehne, Guenther; Barnett-Griness, Ofra; Bibliowicz, Aida; Fathi, Reza; Anderson, Patricia; Raday, Gilead; Eagle, Gina; Katz Ben-Yair, Vered; Minkowitz, Harold S.; Levitt, Mark L.; Gordon, Michael S.
title: Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial
date: 2022-05-11
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac232
sha: 02e1e42dd4db4f2af185261aa13c851435276a76
doc_id: 78827
cord_uid: hrx0l65r

BACKGROUND: Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit SARS-CoV-2 replication in vitro. We thus considered that opaganib could be beneficial for moderate to severe COVID-19 pneumonia. The objective of the study was to evaluate the safety of opaganib and its effect on supplemental oxygen requirements and time to hospital discharge in COVID-19 pneumonia hospitalized patients requiring supplemental oxygen. METHODS: This Phase 2a, randomized, double-blind, placebo-controlled study was conducted between July and December 2020 in eight sites in the USA. Forty-two enrolled patients received opaganib (n = 23) or placebo (n = 19) added to standard of care for up to 14 days and were followed up for 28 days after their last dose of opaganib/placebo. RESULTS: There were no safety concerns arising in this study. The incidence of ≥ Grade 3 treatment-emergent adverse events was 17.4% and 33.3% in the opaganib and placebo groups, respectively. Three deaths occurred in each group. A numerical advantage for opaganib over placebo was observed in in this non-powered study reflected by total supplemental oxygen requirement from baseline to Day 14, the requirement for supplemental oxygen for at least 24 hours by Day 14, and hospital discharge. CONCLUSIONS: In this proof-of-concept study, hypoxic, hospitalized patients receiving oral opaganib had a similar safety profile to placebo-treated patients, with preliminary evidence of benefit for opaganib as measured by supplementary oxygen requirement and earlier hospital discharge. These findings support further evaluation of opaganib in this population.

Acute pneumonia due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 2 infection leading to coronavirus disease 2019 can be life-threatening. Typical 3 symptoms of SARS-CoV-2 infection include fever, fatigue, dry cough, shortness of breath, 4 but can evolve to acute respiratory distress syndrome. Among patients with COVID-19, 80% 5 present with symptoms of mild to moderate severity, with or without pneumonia, while 5-6 14% develop serious or critical respiratory disease, requiring intensive care unit support (1) (2) (3) (4) (5) (6) (7) 3). The mortality rate of COVID-19 ranges from 0.1 to 19.7%, depending on country of 8 origin, socioeconomic background, comorbidities such as diabetes and cardiovascular 9 disease, and disease severity (4) (5) (6) (7) (8) . These comorbidities and advanced age (especially > 65 10 years) increase the risk of mortality (9, 10).

Hospitalized COVID-19 patients often require supplemental oxygen to maintain adequate 12 oxygenation (3, 9) . Some pharmacological agents (corticosteroids and remdesivir) have been 13 widely used as standard of care (SoC), with remdesivir first approved in the USA for 14 emergency use in hospitalized COVID-19 patients in May 2020 (11).

Opaganib (RedHill Biopharma) is a first-in-class orally available, small molecule, selective 16 sphingosine kinase-2 (SK-2) inhibitor with antiviral and anti-inflammatory properties (12) . 17 Multiple ongoing clinical trials are evaluating opaganib as therapy for cancer. The antiviral 18 effect of opaganib was demonstrated in various preclinical studies. Reid and colleagues 19 showed that decreased expression or pharmacologic inhibition of SK-2 significantly inhibited 20 Chikungunya virus replication (13) . In a work by Xia et al., opaganib was shown to reduce 21 fatality rates from influenza A infection in mice (14) . Moreover, in a preliminary study using 22 an in vitro model of human bronchial tissue, we recently demonstrated that opaganib has 23 potent antiviral activity against SARS-CoV-2 (15). We hypothesized that the antiviral and 24 anti-inflammatory effects of opaganib would be beneficial for the treatment of SARS-CoV-2

infection, particularly for patients with moderate to severe COVID-19 pneumonia requiring 1 supplemental oxygen. In a small cohort of patients with severe COVID-19 pneumonia, where 2 opaganib was offered through compassionate use, it appeared to improve clinical and 3 laboratory parameters, and was safe and well tolerated (16) . 4 This Phase 2a proof-of-concept study was designed to provide a preliminary evaluation of the 5 safety and efficacy of opaganib when added to SoC in hospitalized patients with COVID-19 6 pneumonia who required supplemental oxygen. Aside from safety and tolerability 7 assessments, efficacy endpoints measured included change in oxygen requirements and 8 clinical improvement parameters.

This was a Phase 2a, proof-of-concept, multi-center, randomized, double-blind, parallel arm, 12 placebo-controlled study conducted in eight sites in the USA. The study was not powered for 13 efficacy. Eligible patients received opaganib or matching placebo twice daily added to SoC 14 (per regional, institutional/physician practices). Eligible participants were adults (18-80 years 15 inclusively), with SARS-CoV-2 infection determined by polymerase-chain-reaction (PCR) 16 analysis in a nasopharyngeal sample, and pneumonia determined by chest X-ray. The full list 17 of eligibility criteria is provided in the supplementary data (Section-1).

Participants were randomized 1:1 to receive 2 x 250 mg opaganib oral capsules or matching 20 placebo every 12 hours for up to 14 days ( . This dose had been determined in a 21 Phase 1 clinical study in oncology patients as the maximum safe and tolerable dose (17). 22 Patients discharged prior to/at Day 10 completed only 10 days of treatment. After their last 23 study drug dose, participants were followed for up to 28 days (safety follow-up). Treatment 24 assignments remained blinded to the patients, investigators, hospital staff, and sponsor Given the exploratory nature of this proof-of-concept study, we sought to evaluate several 6 clinically meaningful outcomes. We designed a primary outcome measure comparing total characteristics are presented for the Intent-to-Treat (ITT) population (all randomized 1 patients). Safety evaluations were performed for the safety population (patients who took at 2 least one dose of study drug). Efficacy endpoints were analyzed for the modified ITT (mITT) 3 population (patients who took at least one dose of study drug).

A diagram of the study flow is presented in Figure 1 . The ITT population comprised of 42 6 eligible patients, enrolled July-November 2020. Of these, 23 patients were randomized to 7 receive opaganib and 19 patients were randomized to receive placebo (randomization details 8 are provided in the supplementary data, Section-4). One patient in each group did not receive 9 study drug and was excluded from the safety and mITT populations. One patient randomized 10 to placebo was mistakenly given opaganib on Days 10 and 11. 11 Demographic and other baseline characteristics 12 The main demographic and baseline characteristics of patients in the ITT population are 13 presented in Table 1 . Most patients were male (64.3%) with an overall median age of 58.0 14 years. Randomization resulted in a difference between the opaganib and placebo arms in 15 median age (years; 52.0 and 61.0, respectively), and median baseline oxygen requirement 16 (L/min; 6.0 and 10.5, respectively). The median time (days) from from onset of symptoms to 17 randomization was 10.0 for the opaganib group and 9.0 for placebo. 18 Remdesivir and/or high dose corticosteroids (dexamethasone, prednisone, and patients. This included remdesivir in 10 (43.5%) patients on opaganib and nine (50.0%) on 22 placebo, and high dose corticosteroids in 21 (91.3%) and all 18 (100%) patients, respectively.

Compliance was assessed in a subset of the safety population comprising of 21 patients on 2 opaganib and 18 patients on placebo (further details are provided in the supplementary data, 3 Section-5). For two patients on opaganib, compliance was not defined: for the patient 4 randomized to placebo who took opaganib on one day, the expected number of opaganib 5 doses was zero; the second patient was lost to follow up, thus compliance could not be 6 assessed. The mean (±standard deviation) compliance was 90.05% (±21.523) in the opaganib 7 and 98.41% (±3.917) in the placebo groups, respectively. The incidence of TEAEs was similar between groups (52.2%, in the opaganib group versus 10 50.0% in the placebo group; Table 2 ). Generally, each unique TEAE term was reported 11 singly by one patient (either in the opaganib or placebo group). The only TEAEs reported by 12 two patients (8.7% in the opaganib group), and with a higher incidence in the opaganib group 13 than in placebo, were hypokalemia (reported in one patient on placebo), and diarrhea (not 14 reported in patients on placebo).

TESAEs were reported in 13.0% of patients on opaganib and 27.8% patients on placebo. The Renal and urinary disorders (4.3% and 11.1%, respectively). None of the TESAEs were 20 deemed as treatment related by the Investigator.

TEAEs of Grade 3 and above were reported in four patients (17.4%) on opaganib and six 22 patients (33.3%) on placebo, with no TEAEs of Grade 3 and above reported at a higher 23 frequency in the opaganib group compared to placebo (Table 2) . Treatment related TEAEs 24 were recorded in two patients in the opaganib group, including one patient with Grade 1

diarrhea and one patient with Grade 3 rash. Both events were non-serious, and in both cases, 1 the drug was withdrawn, and the patients recovered. Three death cases were reported in each group, which occurred due to COVID-19 10 pneumonia, sepsis, and respiratory failure in the opaganib arm; and due to acute kidney 11 injury, and respiratory failure (two cases) in placebo. None of the deaths were assessed by the 12 Investigator as related to the treatment. 13 In addition to the safety analysis, several efficacy analyses (presented below) were performed 14 with the aim of providing initial data on potential beneficial effects of opaganib in the study 15 population. As the study was not powered for efficacy, the findings from these analyses 16 provide a preliminary evaluation of opaganib's potential benefits, and should be regarded as 17 such.

Total supplemental oxygen requirement using the maximal daily oxygen flow over 14 19 days 20 A relative benefit derived for each group was calculated (as described in the supplementary 21 data, Section-2). The relative benefit calculated was 61.6% for opaganib (n=21) and 46.7% 22 for placebo (n=18) ( Figure S1 ). This was a post-hoc analysis to the pre-defined primary 23 endpoint; as more information on the course of COVID-19 pneumonia became available, this The cumulative incidence for no longer requiring supplemental oxygen for at least 24 hours 4 by Day 14, was estimated using the Kaplan-Meier analysis. The analysis showed a higher 5 estimated cumulative incidence in patients on opaganib (50%) compared to those on placebo 6 (22.2%) ( Figure S2 , Table 1 ).

The subgroup analysis based on SoC regimen showed consistent findings in patients on high-8 dose corticosteroids and patients on remdesivir and corticosteroids. (Table 1 ). Specifically, Table   12   S1 ).

This proof-of-concept study explored the safety and effectiveness of oral opaganib in 15 hospitalized patients with COVID-19 pneumonia requiring supplemental oxygen. Opaganib's 16 safety profile in this study was not materially different than that of placebo. Results suggest 17 clinical improvement as measured by reduced need for supplemental oxygen, improved 18 WHO level in the scale for clinical improvement and in time to discharge (Table S2) . preclinical study using an in vitro model of human bronchial tissue (15) and was associated 2 with favorable outcomes when offered through compassionate use to patients with moderate 3 to severe COVID-19 pneumonia requiring supplemental oxygen via high-flow nasal cannulae 4 (16) . As opaganib targets a host cell factor rather than the virus directly, development of 5 resistance is less likely. This is of particular interest in SARS-CoV-2 infection, given its 6 rapidly emerging mutations and viral strains. The antiviral agent remdesivir has been approved for treatment in certain stages of COVID-8 19; however, it is administered intravenously and lacks anti-inflammatory properties (5), 9 while opaganib is an oral agent with both antiviral and anti-inflammatory properties. 10 Moreover, opaganib is stable at room temperature for five years (RedHill Biopharma Ltd., 11 unpublished data). These factors support opaganib as a much needed, practical and 12 convenient potential treatment of COVID-19 pneumonia. 13 Opaganib was shown to be well-tolerated in this study, with no new safety signals emerging.

14 The only TEAE of Grade 3 and above reported at a higher frequency in the opaganib group 15 than placebo was a Grade 3 rash in a single patient, that resolved upon stopping study drug. 16 Rash is a known uncommon toxicity of opaganib. Three patients on opaganib and five 17 patients on placebo experienced TESAEs. TEAEs leading to treatment withdrawal were 18 reported in 17.4% of patients on opaganib, and 5.6% of patients on placebo. By the safety 19 follow-up timepoint, there were three deaths recorded in each group, none deemed treatment 20 related. The overall incidence of TEAEs and TESAEs were similar in both treatment groups.

The current study was not powered for efficacy, and as such, its efficacy findings provide a Additionally, the mean baseline oxygen requirement (L/min) was lower in the opaganib 11 group (6.0) than in placebo (10.5). As younger individuals are expected to have generally 12 better disease outcomes than their older counterparts, we cannot rule out that these 13 imbalances may have impacted the preliminary efficacy results of the study, contributing to 14 opaganib's observed benefit in the studied population. However, such potential impact 15 remains hypothetical, as most studies looking at the effect of age on disease severity, report 16 the age of > 65 years as a risk factor.

The main limitation of this study is its small sample size, allowing for descriptive analyses 19 rather than meaningful statistical interpretation. A further limitation is the imbalance in age 20 and supplemental oxygen requirement at baseline, a result of the small sample size despite 21 randomization. The clinical interpretation of the primary endpoint was limited, as described 22 in the Discussion, leading to the addition of post-hoc analyses to help with the overall 23 interpretation of the data. An additional limitation of the study is that certain pre-defined 24 secondary endpoints that relied on inpatient data collection could not be assessed due to 

SARS-CoV-2 and the pandemic of COVID-19

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)

Clinical course of COVID-19 patients needing supplemental 9 oxygen outside the intensive care unit

Lopinavir-ritonavir in patients admitted to hospital with 14 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The 15

Repurposed Antiviral Drugs for Covid-19 -Interim 17 WHO Solidarity Trial Results

Health Inequalities During COVID-19 and Their Effects on 21 Morbidity and Mortality

the Northwell COVID-19 Research Consortium

Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the 6

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Pharmacology and Antitumor Activity of ABC294640, a Selective 16 Inhibitor of Sphingosine Kinase-2

Sphingosine kinase 2 is a chikungunya virus host factor co-19 localized with the viral replication complex

Transient inhibition of 21 sphingosine kinases confers protection to influenza A virus infected mice

Patients with Severe COVID-19

A Phase I 4

Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor

Advanced Solid Tumors

COVID-19 Therapeutic Trial Synopsis

Transient inhibition of 9 sphingosine kinases confers protection to influenza A virus infected mice

Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and 14 epigenetic regulation of lung inflammatory injury

Pharmacologic 16 Manipulation of Sphingosine Kinase in Retinal Endothelial Cells: Implications for 17

Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of 20